Bullish indicating open at $55-$60, IPO prices at $37
YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biotech company with a market capitalization of $203 million and strong financial health indicators according to InvestingPro data, announced new data demonstrating a strong correlation between wound bed preparation and wound closure in patients with venous leg ulcers, according to a post hoc analysis published in Advances in Wound Care.
The analysis examined 119 patients with chronic venous leg ulcers who received treatments with either EscharEx, a placebo gel, or standard care. Results showed that wounds failing to achieve wound bed preparation had a 90% probability of not healing, while wounds that did achieve proper preparation were 4.1 times more likely to close. With three analysts recently revising earnings estimates upward, market confidence in the company’s clinical progress appears to be growing.
Early achievement of wound bed preparation, defined as complete removal of nonviable tissue and full coverage with healthy granulation tissue, was associated with a 2.4 times higher likelihood of healing. Wounds that failed to reach proper preparation had a 12-fold higher risk of remaining unhealed throughout the study period.
"While wound bed preparation has long been accepted as the conceptual foundation for managing chronic wounds, this landmark analysis provides evidence, for the first time, that there is a strong correlation between the two," said Dr. Marissa J. Carter, a clinical trial specialist quoted in the press release.
EscharEx is a bromelain-based enzymatic therapy in development for debridement of chronic wounds. The company is currently conducting a global Phase III study in venous leg ulcers and preparing a clinical study in diabetic foot ulcers.
MediWound specializes in developing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved product NexoBrid is indicated for enzymatic removal of eschar in thermal burns.
The information in this article is based on a company press release statement.
In other recent news, MediWound Ltd reported its first-quarter 2025 financial results and provided updates on its clinical programs. The company is actively progressing with its Phase 3 VALUE study, which involves 216 patients and assesses the efficacy of EscharEx for treating venous leg ulcers. Most U.S. sites are operational, and European centers are expected to start in the third quarter of 2025. Oppenheimer analysts assumed coverage of MediWound with an Outperform rating and set a price target of $34, slightly adjusting from the previous target of $36. Meanwhile, H.C. Wainwright increased the price target to $31 from $25, maintaining a Buy rating. A post hoc analysis published in the journal Wounds highlighted that EscharEx might offer clinical advantages over the FDA-approved treatment SANTYL, achieving faster and more complete debridement in the Phase II ChronEx trial. The study showed that 63% of patients using EscharEx achieved complete debridement in two weeks, compared to none in the SANTYL group. Additionally, half of the EscharEx patients reached complete wound bed preparation within the same timeframe. These developments reflect MediWound’s ongoing efforts in clinical and commercial advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.